5 Stocks Dragging In The Health Care Sector

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 44 points (-0.3%) at 15,515 as of Monday, July 29, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 829 issues advancing vs. 2,095 declining with 99 unchanged.

The Health Care sector currently sits down 0.2% versus the S&P 500, which is down 0.4%. On the negative front, top decliners within the sector include Haemonetics Corporation ( HAE), down 8.7%, Perrigo Company ( PRGO), down 6.7%, Dr. Reddy Laboratories ( RDY), down 3.3%, Alexion Pharmaceuticals ( ALXN), down 2.6% and Teva Pharmaceutical Industries ( TEVA), down 2.3%. Top gainers within the sector include Alkermes ( ALKS), up 5.3%, Shire ( SHPG), up 1.2% and WellPoint ( WLP), up 1.2%.

TheStreet would like to highlight 5 stocks pushing the sector lower today:

5. Biogen Idec ( BIIB) is one of the companies pushing the Health Care sector lower today. As of noon trading, Biogen Idec is down $5.18 (-2.3%) to $218.05 on average volume. Thus far, 640,720 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $217.01-$224.11 after having opened the day at $221.86 as compared to the previous trading day's close of $223.23.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $54.0 billion and is part of the drugs industry. Shares are up 55.4% year to date as of the close of trading on Friday. Currently there are 12 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, solid stock price performance and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Biogen Idec Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, Amgen ( AMGN) is down $0.61 (-0.6%) to $108.99 on light volume. Thus far, 749,917 shares of Amgen exchanged hands as compared to its average daily volume of 3.4 million shares. The stock has ranged in price between $108.42-$109.80 after having opened the day at $109.58 as compared to the previous trading day's close of $109.60.

Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Amgen has a market cap of $82.1 billion and is part of the drugs industry. Shares are up 27.0% year to date as of the close of trading on Friday. Currently there are 8 analysts that rate Amgen a buy, no analysts rate it a sell, and 13 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, attractive valuation levels, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Amgen Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Celgene Corporation ( CELG) is down $1.61 (-1.1%) to $142.33 on light volume. Thus far, 979,859 shares of Celgene Corporation exchanged hands as compared to its average daily volume of 3.0 million shares. The stock has ranged in price between $141.62-$143.79 after having opened the day at $142.00 as compared to the previous trading day's close of $143.94.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Celgene Corporation has a market cap of $58.7 billion and is part of the drugs industry. Shares are up 79.2% year to date as of the close of trading on Friday. Currently there are 23 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, notable return on equity and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Celgene Corporation Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Bristol-Myers Squibb Company ( BMY) is down $0.28 (-0.6%) to $43.94 on average volume. Thus far, 4.3 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 10.6 million shares. The stock has ranged in price between $43.82-$44.32 after having opened the day at $44.11 as compared to the previous trading day's close of $44.22.

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $72.2 billion and is part of the drugs industry. Shares are up 34.8% year to date as of the close of trading on Friday. Currently there are 6 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 12 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Bristol-Myers Squibb Company Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Gilead ( GILD) is down $0.40 (-0.6%) to $62.17 on average volume. Thus far, 4.6 million shares of Gilead exchanged hands as compared to its average daily volume of 11.1 million shares. The stock has ranged in price between $61.57-$62.60 after having opened the day at $62.60 as compared to the previous trading day's close of $62.57.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $92.8 billion and is part of the drugs industry. Shares are up 65.7% year to date as of the close of trading on Friday. Currently there are 18 analysts that rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, increase in net income, expanding profit margins and growth in earnings per share. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Gilead Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Global Stocks Slide as Trump's New Trade War Salvo Ignites Fresh Concern

Global Stocks Slide as Trump's New Trade War Salvo Ignites Fresh Concern

Trump Tariff Threat, Deutsche Bank, Elon Musk and Apple - 5 Things You Must Know

Trump Tariff Threat, Deutsche Bank, Elon Musk and Apple - 5 Things You Must Know

Automakers Slump as Trump Launches National Security Probe into US Car Imports

Automakers Slump as Trump Launches National Security Probe into US Car Imports

Deutsche Bank Confirms Massive Job Cuts as New CEO Christian Sewing Plants Flag

Deutsche Bank Confirms Massive Job Cuts as New CEO Christian Sewing Plants Flag

Carnival CEO Arnold Donald: China Will Become the Largest Cruise Market

Carnival CEO Arnold Donald: China Will Become the Largest Cruise Market